131 related articles for article (PubMed ID: 35791694)
1. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.
Willis JA; Overman MJ
Cancer Discov; 2022 Jul; 12(7):1612-1614. PubMed ID: 35791694
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Crisafulli G; Sartore-Bianchi A; Lazzari L; Pietrantonio F; Amatu A; Macagno M; Barault L; Cassingena A; Bartolini A; Luraghi P; Mauri G; Battuello P; Personeni N; Zampino MG; Pessei V; Vitiello PP; Tosi F; Idotta L; Morano F; Valtorta E; Bonoldi E; Germano G; Di Nicolantonio F; Marsoni S; Siena S; Bardelli A
Cancer Discov; 2022 Jul; 12(7):1656-1675. PubMed ID: 35522273
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
5. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
Pietrantonio F; Randon G; Romagnoli D; Di Donato S; Benelli M; de Braud F
Cancer Treat Rev; 2020 Jan; 82():101935. PubMed ID: 31821983
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
Haag GM; Springfeld C; Grün B; Apostolidis L; Zschäbitz S; Dietrich M; Berger AK; Weber TF; Zoernig I; Schaaf M; Waberer L; Müller DW; Al-Batran SE; Halama N; Jaeger D
Eur J Cancer; 2022 May; 167():112-122. PubMed ID: 35427833
[TBL] [Abstract][Full Text] [Related]
8. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.
Willis JA; Overman MJ; Vilar E
Clin Cancer Res; 2019 Sep; 25(17):5185-5187. PubMed ID: 31263028
[TBL] [Abstract][Full Text] [Related]
9. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
10. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
11. Advances in immunotherapy for MMR proficient colorectal cancer.
Lote H; Starling N; Pihlak R; Gerlinger M
Cancer Treat Rev; 2022 Dec; 111():102480. PubMed ID: 36335756
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Colorectal Cancer.
Mukherji R; Weinberg BA; Pedersen KS
Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
[TBL] [Abstract][Full Text] [Related]
13. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
[TBL] [Abstract][Full Text] [Related]
18. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
[TBL] [Abstract][Full Text] [Related]
19. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
20. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]